Event preview: Life Sciences IP Due Diligence summit

The Annual Summit on Life Sciences IP Due Diligence to be held on November 14 and 15 in Boston, MA, is a one-of-a-kind, interactive forum where diligence experts discuss best practices and strategies for executing a proper IP due diligence analysis for incumbent portfolios and those of potential targets.

The continued success of a life sciences company hinges upon successful partnerships. There are many corporate transactions involving life sciences IP that necessitate conducting due diligence.

These include engaging team members in the face of a merger or acquisition, an initial public offering, venture capital financing, in-licensing, partnering, co-development, or distribution agreements. Structuring due diligence is entirely dependent upon the objectives.

The third Annual Summit on Life Sciences IP Due Diligence provides a forum for industry stakeholders to master how to cultivate, navigate, and apply the results of an effective and profitable due diligence analysis.

Attendees will benefit from in-depth sessions helping them to:

• Identify criteria that impact the overall value of the deal during the IP valuation process;
• Conduct international legal risk assessments and find appropriate resources for IP due diligence examinations;
• Find funding options to facilitate business expansion and accelerate growth;
• Mitigate the inherent risks presented in life sciences IP due diligence investigations; and
• Negotiate and draft the relevant documents to ensure a detailed, robust and accurate agreement.

There will also be opportunities to network and benchmark strategies with professionals from life sciences companies including Akeba Therapeutics, Alexion Pharmaceuticals, Celgene, Dana-Farber Cancer Institute, Novartis Institutes for BioMedical Research, and Stryker.

LSIPR readers can benefit from a unique opportunity to register here for the event and receive a 10% discount with the code: D10-657-657EX01.